Could cause temporary or reversible harm; serious harm is unlikely.
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
| Brand name | OZEMPIC |
| Generic name | SEMAGLUTIDE |
| Active ingredient(s) | SEMAGLUTIDE |
| Distributed by / for | Novo Nordisk Inc |
| NDC | 0169-4132-90 |
| Full product label | OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit) |
| Recalling firm | Novo Nordisk Inc |
| Distribution | Nationwide in the USA |
| Quantity | N/A |
| Recall initiated | 2021-03-22 |
| Report date | 2021-04-21 |
| Recall completed | 2022-12-09 |
| Recall number | D-0617-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Plainsboro NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗